Revenue: The sum of all revenue fields included for a company's operating activities.
Xeris Biopharma Holdings, Inc. (XERS) had Revenue of $60.12M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
|
Revenue |
$60.12M |
$-9.22M |
|
$8.73M |
|
$51.39M |
|
$63.21M |
|
$-3.09M |
|
$-6.13M |
|
$-9.22M |
|
$-9.22M |
|
$-9.22M |
|
$-9.22M |
|
$-9.22M |
|
$-9.22M |
|
$-3.09M |
|
$0.90M |
|
152.45M |
|
152.45M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$163.49M |
|
$5.26M |
|
$151.96M |
|
$315.45M |
|
$95.07M |
|
$217.81M |
|
$255.51M |
|
$350.58M |
|
$-35.13M |
|
$-154.20M |
|
$-35.13M |
|
156.01M |
|
| Cash Flow Statement Financials | |
$-10.03M |
|
$-0.01M |
|
$-3.14M |
|
$75.74M |
|
$62.56M |
|
$-13.18M |
|
$4.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.72 |
|
-- |
|
-- |
|
1.19 |
|
-6.54 |
|
85.48% |
|
-5.14% |
|
-5.14% |
|
-- |
|
-15.34% |
|
-15.34% |
|
$-10.04M |
|
-- |
|
-- |
|
-- |
|
0.19 |
|
0.17 |
|
1.30 |
|
69.36 |
|
26.25% |
|
5.98% |
|
-2.92% |
|
-5.05% |
|
$-0.23 |
|
$-0.07 |
|
$-0.07 |
|